• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年人糖尿病的治疗方法

Approach Toward Diabetes Treatment in the Elderly.

作者信息

Altuntaş Yüksel

机构信息

Department of Endocrinology and Metabolism, University of Health Sciences Sisli Hamidiye Etfal Training and Resarch Hospital, Istanbul, Turkey.

出版信息

Sisli Etfal Hastan Tip Bul. 2019 Jun 25;53(2):96-102. doi: 10.14744/SEMB.2019.00868. eCollection 2019.

DOI:10.14744/SEMB.2019.00868
PMID:32377065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7199825/
Abstract

Concomitant diseases in elderly individuals with diabetes (renal failure, heart failure, ischemic heart disease, stroke, urinary incontinence, cognitive impairment, dementia, sarcopenia, and osteoporosis) make diabetes management difficult. Therefore, other comorbid conditions should be taken into account in elderly diabetics when considering a treatment approach. The use of oral antidiabetic agents in individuals older than 75 years may be limited. Although the diabetes treatment is not any different in healthy elderly patients, hypoglycemia is one of the most feared conditions, especially in the elderly. Therefore, metformin, DPP-IV inhibitors, and SGLT2 inhibitors should be considered in the first place with less risk of hypoglycemia. Low-dose sulfonylureas may also be used in selected cases. The use of new antidiabetic drugs, such as GLP-1 anologues and SGLT2 inhibitors, has strengthened our ability to cope with the risk of hypoglycemia and cardiovascular events, which are the two most important drawbacks in the treatment of elderly people with diabetes. Insulin treatment should be individualized, and the most rare injection regimens should be used. In case of failure of OAD, basal insulin should be added to the current treatment, and if necessary, a basal + plus regimen should be planned by adding bolus insulin 1/2/3 times per day to the meals. As a result, in elderly diabetics, an inadequate treatment or excessive treatment and individualizing the treatment should be the most appropriate approach.

摘要

老年糖尿病患者的合并症(肾衰竭、心力衰竭、缺血性心脏病、中风、尿失禁、认知障碍、痴呆、肌肉减少症和骨质疏松症)使得糖尿病管理变得困难。因此,在考虑治疗方法时,老年糖尿病患者应考虑其他合并症。75岁以上人群口服降糖药的使用可能受到限制。虽然健康老年患者的糖尿病治疗并无不同,但低血糖是最令人担忧的情况之一,尤其是在老年人中。因此,应首先考虑使用低血糖风险较低的二甲双胍、二肽基肽酶-4(DPP-IV)抑制剂和钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂。在特定情况下也可使用小剂量磺脲类药物。新型降糖药物如胰高血糖素样肽-1(GLP-1)类似物和SGLT2抑制剂的使用,增强了我们应对低血糖风险和心血管事件的能力,这是老年糖尿病患者治疗中两个最重要的缺点。胰岛素治疗应个体化,并应采用最简便的注射方案。如果口服降糖药治疗失败,应在当前治疗基础上加用基础胰岛素,如有必要,可通过每天1/2/3次在进餐时加用餐时胰岛素来制定基础加餐时胰岛素方案。因此,对于老年糖尿病患者,不充分治疗或过度治疗以及个体化治疗应是最合适的方法。

相似文献

1
Approach Toward Diabetes Treatment in the Elderly.老年人糖尿病的治疗方法
Sisli Etfal Hastan Tip Bul. 2019 Jun 25;53(2):96-102. doi: 10.14744/SEMB.2019.00868. eCollection 2019.
2
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.在 2 型糖尿病患者中,与磺酰脲类药物相比,添加二肽基肽酶-4 抑制剂对临床结局的影响。
Ann Intern Med. 2015 Nov 3;163(9):663-72. doi: 10.7326/M15-0308. Epub 2015 Oct 13.
3
Pharmacologic management of the older patient with type 2 diabetes mellitus.老年2型糖尿病患者的药物治疗
Am J Geriatr Pharmacother. 2009 Dec;7(6):324-42. doi: 10.1016/j.amjopharm.2009.12.002.
4
Oral antidiabetic agents: current role in type 2 diabetes mellitus.口服抗糖尿病药物:在2型糖尿病中的当前作用
Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005.
5
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.瑞格列奈:对其在2型糖尿病治疗中应用的药物经济学综述
Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005.
6
Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.二甲双胍加磺脲类药物治疗失败后2型糖尿病治疗的网状Meta分析
Curr Med Res Opin. 2016 May;32(5):807-16. doi: 10.1185/03007995.2015.1135110. Epub 2016 Feb 29.
7
EADSG Guidelines: Insulin Therapy in Diabetes.欧洲糖尿病研究学会指南:糖尿病的胰岛素治疗
Diabetes Ther. 2018 Apr;9(2):449-492. doi: 10.1007/s13300-018-0384-6. Epub 2018 Mar 5.
8
Complementing insulin therapy to achieve glycemic control.补充胰岛素治疗以实现血糖控制。
Adv Ther. 2013 Jun;30(6):557-76. doi: 10.1007/s12325-013-0039-y.
9
New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.老年2型糖尿病的新型治疗方法:肠促胰岛素疗法的作用
Drugs Aging. 2008;25(11):913-25. doi: 10.2165/0002512-200825110-00002.
10
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?2型糖尿病患者中DPP-4抑制剂与胰岛素联合治疗:证据有哪些?
Hosp Pract (1995). 2013 Apr;41(2):93-107. doi: 10.3810/hp.2013.04.1059.

引用本文的文献

1
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data.钠-葡萄糖协同转运蛋白2抑制剂对射血分数降低的老年心力衰竭患者的影响:真实世界数据
Biomedicines. 2024 Jul 7;12(7):1507. doi: 10.3390/biomedicines12071507.
2
Comparison of the effect of Dapagliflozin and Pioglitazone on the risk of osteoporosis in postmenopausal women with Type-2 diabetes.达格列净与吡格列酮对2型糖尿病绝经后女性骨质疏松症风险影响的比较
Pak J Med Sci. 2023 Sep-Oct;39(5):1238-1242. doi: 10.12669/pjms.39.5.7580.
3
Defining explicit definitions of potentially inappropriate prescriptions for antidiabetic drugs in patients with type 2 diabetes: A systematic review.明确界定 2 型糖尿病患者抗糖尿病药物潜在不适当处方的定义:系统评价。
PLoS One. 2022 Sep 12;17(9):e0274256. doi: 10.1371/journal.pone.0274256. eCollection 2022.
4
Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.依帕列净与二甲双胍对老年2型糖尿病患者内脏脂肪减少作用的比较:一项随机对照研究的亚组分析
Diabetes Ther. 2021 Jan;12(1):183-196. doi: 10.1007/s13300-020-00949-0. Epub 2020 Oct 24.

本文引用的文献

1
Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management.磺脲类药物和瑞格列奈在老年患者中的低血糖副作用——知识与自我管理
J Physiol Pharmacol. 2018 Aug;69(4). doi: 10.26402/jpp.2018.4.15. Epub 2018 Dec 9.
2
International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.国际肌少症临床实践指南(ICFSR):筛查、诊断和管理。
J Nutr Health Aging. 2018;22(10):1148-1161. doi: 10.1007/s12603-018-1139-9.
3
The Therapeutic Potential of Metformin in Neurodegenerative Diseases.二甲双胍在神经退行性疾病中的治疗潜力
Front Endocrinol (Lausanne). 2018 Jul 19;9:400. doi: 10.3389/fendo.2018.00400. eCollection 2018.
4
Epigenetic effects of metformin: From molecular mechanisms to clinical implications.二甲双胍的表观遗传学效应:从分子机制到临床意义。
Diabetes Obes Metab. 2018 Jul;20(7):1553-1562. doi: 10.1111/dom.13262. Epub 2018 Mar 22.
5
Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.每周一次艾塞那肽与基础胰岛素治疗在美国新诊断的老年或肾功能不全的 2 型糖尿病患者中的有效性和耐受性比较。
Diabetes Obes Metab. 2018 Apr;20(4):898-909. doi: 10.1111/dom.13175. Epub 2018 Jan 3.
6
Glitazone use associated with reduced risk of Parkinson's disease.吡格列酮的使用与帕金森病风险降低相关。
Mov Disord. 2017 Nov;32(11):1594-1599. doi: 10.1002/mds.27128. Epub 2017 Sep 1.
7
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
8
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
9
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.达格列净在老年2型糖尿病患者中的长期安全性:一项IIb/III期研究的汇总分析
Drugs Aging. 2016 Jul;33(7):511-22. doi: 10.1007/s40266-016-0382-1.
10
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.